Novel approach to pro-drugs of lactones: Water soluble imidate and ortho-ester derivatives of a furanone-based COX-2 selective inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 9, 2005, Pages 2259-2263

  Poon, Steve F ^a   Stock, Nicholas ^a   Payne, Joseph E ^a   McGuire, Angela R ^a   Stearns, Brian ^a   Yang, Xiaoqing ^a   Chen, Weichao ^a   Munoz, Benito ^a   Smith, Nicholas D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

COX 2; ortho Ester; Pro drug; Stroke

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ESTER DERIVATIVE; FURANONE DERIVATIVE; LACTONE DERIVATIVE; PRODRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VIVO STUDY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TECHNIQUE;

EID: 17144421595     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.03.009     Document Type: Article

References (13)

1. K.S. Lewis, J.K. Whipple, K.A. Michael, and E.J. Quebbeman Am. J. Hosp. Pharm. 51 1994 1539
2. S.D. Hurley, J.A. Olschowka, and M.K. O'Banion J. Neurotrauma 19 2002 1
3. J.J. Talley, S.R. Bertenshaw, D.L. Brown, J.S. Carer, M.J. Branetto, M.S. Kellogg, C.M. Koboldt, J. Yuan, Y.Y. Zhang, and K. Seibert J. Med. Chem. 43 2000 1661
4. C. Almansa, J. Bartroli, J. Belloc, F.L. Cavalcanti, R. Ferrando, L.A. Gomez, I. Ramis, E. Carceller, M. Merlos, and J. Garcia-Rafanell J. Med. Chem. 47 2004 5579
5. M. Pal, M. Madan, S. Pdakanti, V.R. Pattabirman, S. Kalleda, A. Vanguri, R. Mullangi, N.V.S.R. Mamidi, S.R. Casturi, A. Malde, B. Gopalakrishnan, and K.R. Yeleswarapu J. Med. Chem. 46 2003 3975
6. W.C. Black, C. Brideau, C.-C. Chan, S. Charleson, W. Cromlish, R. Gordon, E.L. Grimm, G. Hughes, S. Leger, C.S. Li, D. Riendeau, M. Theiren, Z. Wang, L.-J. Xu, and P. Prasit Bioorg. Med. Chem. Lett. 13 2003 1195
7. Y. Leblanc, P. Roy, Z. Wang, C.S. Li, N. Chauret, D.A. Nicoll-Griffith, J.M. Silva, Y. Aubin, J.A. Yergey, C.C. Chan, D. Riendeau, C. Brideau, R. Gordon, L. Xu, J. Webb, D.M. Visco, and P. Prasit Bioorg. Med. Chem. Lett. 12 2002 3317 Note: Compound 2 has been in Phase 2 clinical trials
8. Smith, N. D.; Reger, T.; Payne, J.; Zunic, J.; Lorrain, D.; Correa, L.; Stock, N.; Arruda, J.; Chen, W.; Yang, J.; Prasit, P.; Munoz, B. Bioorg. Med. Chem. Lett., in press
9. The sulfone derivative 2 could not be reduced successfully, therefore sulfide was prepared as described in: Black, C.; Leger, S.; Prasit, P.; Wang, Z.; Hamel, P.; Han, Y.; Hughes, G. U.S. Patent 6,057,319
10. W.H. Pirkle, and T.J. Sowin J. Org. Chem. 52 1987 3011
11. I. Shibuya, E. Katoh, Y. Gama, A. Oishi, Y. Taguchi, and T. Tsuchiya Heterocycles 43 1996 851
12. 3N (0.56 mL, 4.0 mmol) was added dropwise to the reaction. The resulting mixture was filtered through Celite to remove the silver byproducts, and then concentrated under pressure. The crude material was then purified on alumina, yielding an amorphous white solid (80%)
13. M.G. Kulkarni, and S.R. Thopate Tetrahedron 52 1996 1293